The coronary
vasodilator and cardiac effects of
NKY-722, a novel hydrophilic
1,4-dihydropyridine derivative, were evaluated in isolated, blood-perfused sinoatrial (SA) node, atrioventricular (AV) node, and papillary muscle preparations of dogs.
NKY-722 was administered intraarterially.
NKY-722 increased coronary blood flow in all preparations. In SA node preparations,
NKY-722 reduced sinus rate and produced atrial standstill in large doses. The dose that produced a 15% (nearly half-maximum) decrease in sinus rate was about six times the dose that doubled coronary blood flow. In AV node preparations,
NKY-722 prolonged AV conduction time and produced second- or third-degree
AV block in large doses only when administered into the artery supplying the AV node. The dose that produced a 15% (nearly half-maximum) increase in AV conduction time was about 3.5 times the dose that doubled coronary blood flow. In paced papillary muscle preparations,
NKY-722 reduced the force of contraction. However, the dose that produced a 50% decrease in the force of contraction of the paced papillary muscle was about 100 times the dose that doubled coronary blood flow. In spontaneously beating papillary muscle preparations,
NKY-722 failed to change the beating rate. The
vasodilator effect of
NKY-722 was of longer duration than the negative chronotropic, dromotropic, and inotropic effects. These results indicate that
NKY-722 is highly vasoselective, and the cardiovascular profile of
NKY-722 is essentially identical to that of currently available, lipophilic
1,4-dihydropyridine calcium antagonists.